Iovance Biotherapeutics Inc at JPMorgan Healthcare Conference Transcript
All right. Thank you, everybody. I'm pleased to present Iovance's presentation here at the 41st Annual JPMorgan Healthcare Conference.
Before I start, some forward-looking statements I'll be making today, as a disclaimer.
Here's Iovance's final numbers and shows our global leadership in innovating and developing tumor infiltrating lymphocyte or TIL therapy for patients with cancer. We've treated more than 500 patients, by far the industry leader with a 90%-plus manufacturing rate, and we have a 22-day industry-leading manufacturing process. We've got 1 BLA submission in progress right now. We've got 6 active clinical trials with 5 different tumor types in the clinic, which are solid tumors. And we've got 5 separate accelerated designations from the USFDA, 3 Fast Track, 1 breakthrough and on RMAT designation.
As of the end of the third quarter, we had $367 million in cash. We have more than 60 international and U.S. patents, and we have more than 500 people at
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
